456 related articles for article (PubMed ID: 31264484)
1. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
Majd N; de Groot J
Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
[No Abstract] [Full Text] [Related]
2. Immunotherapy for Neuro-Oncology.
Majd N; Dasgupta P; de Groot J
Adv Exp Med Biol; 2020; 1244():183-203. PubMed ID: 32301015
[TBL] [Abstract][Full Text] [Related]
3. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
[No Abstract] [Full Text] [Related]
4. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Neuro-oncology.
Majd NK; Dasgupta PR; de Groot JF
Adv Exp Med Biol; 2021; 1342():233-258. PubMed ID: 34972967
[TBL] [Abstract][Full Text] [Related]
6. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.
Gedeon PC; Champion CD; Rhodin KE; Woroniecka K; Kemeny HR; Bramall AN; Bernstock JD; Choi BD; Sampson JH
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1147-1158. PubMed ID: 32862726
[TBL] [Abstract][Full Text] [Related]
8. Advances in immunotherapy for the treatment of glioblastoma.
Tivnan A; Heilinger T; Lavelle EC; Prehn JH
J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma Immune Landscape and the Potential of New Immunotherapies.
Daubon T; Hemadou A; Romero Garmendia I; Saleh M
Front Immunol; 2020; 11():585616. PubMed ID: 33154756
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of Primary Brain Tumors: Facts and Hopes.
Buerki RA; Chheda ZS; Okada H
Clin Cancer Res; 2018 Nov; 24(21):5198-5205. PubMed ID: 29871908
[TBL] [Abstract][Full Text] [Related]
11. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
12. Recruiting T-Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co-Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage-Membrane-Camouflaged Nanovesicles.
Xu X; Zhang Z; Du J; Xue Y; Chen X; Zhang J; Yang X; Chang D; Xie J; Ju S
Adv Mater; 2023 Jun; 35(25):e2209785. PubMed ID: 37101060
[TBL] [Abstract][Full Text] [Related]
13. Current challenges in designing GBM trials for immunotherapy.
Weathers SP; Gilbert MR
J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401
[TBL] [Abstract][Full Text] [Related]
14. Immunological Aspects of Malignant Gliomas.
Cohen-Inbar O; Zaaroor M
Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
[TBL] [Abstract][Full Text] [Related]
15. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for glioblastoma: the promise of combination strategies.
Bausart M; Préat V; Malfanti A
J Exp Clin Cancer Res; 2022 Jan; 41(1):35. PubMed ID: 35078492
[TBL] [Abstract][Full Text] [Related]
17. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
19. Microglia-Centered Combinatorial Strategies Against Glioblastoma.
Martins TA; Schmassmann P; Shekarian T; Boulay JL; Ritz MF; Zanganeh S; Vom Berg J; Hutter G
Front Immunol; 2020; 11():571951. PubMed ID: 33117364
[TBL] [Abstract][Full Text] [Related]
20. The role of checkpoints in the treatment of GBM.
Kim JE; Lim M
J Neurooncol; 2015 Jul; 123(3):413-23. PubMed ID: 25749875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
